Literature DB >> 2730276

Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings.

C de Montigny1.   

Abstract

A total of 31 intravenous injections of the tetrapeptide cholecystokinin (30-33) were carried out in ten healthy subjects. In seven subjects, cholecystokinin-4 provoked a short-lasting (one to four minutes) panic-like attack (an intense unexplainable fear) at doses between 20 and 100 micrograms. In the other three subjects, doses of 80 to 100 micrograms induced severe anxiety, but no panic-like attack. All subjects experienced severe gastrointestinal symptoms. Pretreatment with lorazepam, but not with meprobamate or naloxone, prevented the psychic effects of cholecystokinin-4 in subjects who had experienced a panic-like attack with the same dose of this peptide. Following the peptide injection, levels of plasma free catecholamines, lactate, and glucose were unchanged, whereas levels of plasma cortisol and prolactin were increased. The intravenous injection of the sulfated cholecystokinin octapeptide (26-33) in two subjects (doses of 35 and 40 micrograms, respectively) produced severe gastrointestinal symptoms, but failed to induce any anxiety or panic-like attacks. These preliminary findings suggest that cholecystokinin-4 may have a panic-inducing effect. It remains to be established if this peptide exerts this effect via a direct activation of central cholecystokinin receptors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2730276     DOI: 10.1001/archpsyc.1989.01810060031006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  55 in total

Review 1.  The genetics of panic disorder.

Authors:  C T Finn; J W Smoller
Journal:  Curr Psychiatry Rep       Date:  2001-04       Impact factor: 5.285

Review 2.  Flushing Disorders Associated with Gastrointestinal Symptoms: Part 2, Systemic Miscellaneous Conditions.

Authors:  Vaibhav Rastogi; Devina Singh; Joseph J Mazza; Dipendra Parajuli; Steven H Yale
Journal:  Clin Med Res       Date:  2018-04-12

Review 3.  Neuropeptide regulation of fear and anxiety: Implications of cholecystokinin, endogenous opioids, and neuropeptide Y.

Authors:  Mallory E Bowers; Dennis C Choi; Kerry J Ressler
Journal:  Physiol Behav       Date:  2012-03-10

4.  Enhanced cortical extracellular levels of cholecystokinin-like material in a model of anticipation of social defeat in the rat.

Authors:  C Becker; M H Thièbot; Y Touitou; M Hamon; F Cesselin; J J Benoliel
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

Review 5.  Neuroendocrine circuits governing energy balance and stress regulation: functional overlap and therapeutic implications.

Authors:  Yvonne M Ulrich-Lai; Karen K Ryan
Journal:  Cell Metab       Date:  2014-03-13       Impact factor: 27.287

Review 6.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

7.  The benzodiazepine antagonist flumazenil blocks the effects of CCK receptor agonists and antagonists in the elevated plus-maze.

Authors:  P Chopin; M Briley
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

8.  Neuropeptidergic signaling partitions arousal behaviors in zebrafish.

Authors:  Ian G Woods; David Schoppik; Veronica J Shi; Steven Zimmerman; Haley A Coleman; Joel Greenwood; Edward R Soucy; Alexander F Schier
Journal:  J Neurosci       Date:  2014-02-26       Impact factor: 6.167

Review 9.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  Cholecystokinin release mediated by 5-HT3 receptors in rat cerebral cortex and nucleus accumbens.

Authors:  P Paudice; M Raiteri
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.